IP Library Granted Patent US 8,378,073
Granted Patent B2
US 8,378,073 · App. 11/994,053 · Granted Feb 19, 2013

Process for attaching effector molecules to proteins

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,378,073
App. No.
11/994,053
Granted
Feb 19, 2013
Kind
B2
Abstract

The present invention provides a process for attaching one or more effector molecules to one or more cysteines in a protein comprising: a) activating one or more cysteines in the protein by diafiltering the protein against a monothiol reducing agent or a multi-thiol reducing agent which is incapable of forming intramolecular disulphide bonds and b) reacting the treated protein with an effector molecule.

Claims (25)

1. A process for attaching one or more effector molecules to one or more cysteines in a protein sample comprising:

a) activating one or more cysteines in the protein sample by commencing diafiltration of the protein sample against a diafiltration buffer, wherein the diafiltration buffer comprises a monothiol reducing agent or a multi-thiol reducing agent which is incapable of forming intramolecular disulphide bonds thereby forming a treated protein, and

b) reacting the treated protein with an effector molecule.

2. The process according to claim 1 in which a monothiol reducing agent or a multi-thiol reducing agent which is incapable of forming intramolecular disulphide bonds is present in the protein sample prior to step (a).

3. The process according to claim 2 in which the concentration of reducing agent in the protein sample is between 0.5 and 1.5 times the concentration of reducing agent in the diafiltration buffer.

4. The process according to claim 3 in which prior to step (a) the concentration of reducing agent in the protein sample is the same as the concentration of reducing agent in the diafiltration buffer.

5. The process according to claim 1 in which the concentration of reducing agent is 1 mM.

6. The process according to claim 1 in which the reducing agent is removed from the protein sample between step (a) and step (b).

7. The process according to claim 6 in which the reducing agent is removed by gel filtration.

8. The process according to claim 6 in which the reducing agent is removed by diafiltration.

9. The process according to claim 1 in which the reducing agent is selected from β-mercaptoethylamine, β-mercaptoethanol, glutathione or cysteine.

10. The process according to claim 1 further comprising step (c) in which the protein with the desired number of effector molecules attached is purified.

11. The process according to claim 1 in which the protein is an antibody or fragment thereof.

12. The process of claim 11 in which the protein is an antibody Fab' fragment.

13. The process according to claim 11 in which at least one cysteine to which an effector molecule is attached is present in the antibody hinge.

14. The process according to claim 13 in which each cysteine to which an effector molecule is attached is present in the antibody hinge.

15. The process according to claim 1 in which the effector molecule is PEG.

16. The process according to claim 15 in which the effector molecule is 40,000 PEG-maleimide.

17. The process according to claim 2 in which the reducing agent is removed from the protein sample between step (a) and step (b).

18. The process according to claim 2 in which the reducing agent is selected from β-mercaptoethylamine, β-mercaptoethanol, glutathione or cysteine.

19. The process according to claim 2 further comprising step (c) in which the protein with the desired number of effector molecules attached is purified.

20. The process according to claim 2 in which the protein is an antibody or fragment thereof.

21. A process for attaching one or more effector molecules to one or more cysteines in a protein sample comprising:

a) activating one or more cysteines in the protein sample, the cysteines that are activated being not in disulphide linkage with another cysteine in the same polypeptide, by diafiltering of the protein sample against a diafiltration buffer, wherein the diafiltration buffer comprises a monothiol reducing agent or a multi-thiol reducing agent which is incapable of forming intramolecular disulphide bonds thereby forming a treated protein, and

b) reacting the treated protein with an effector molecule.

Assignments (2)
CONFIRMATORY ASSIGNMENT Recorded Jun 10, 2016
From: UCB PHARMA, S.A.
To: UCB BIOPHARMA SPRL
Reel/Frame 038953/0312 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jul 3, 2008
From: HEYWOOD, SAM PHILIP
To: UCB PHARMA S.A.
Reel/Frame 021193/0473 →